President Trump nominated Dr. Heidi Overton, deputy director of the White House Domestic Policy Council and a physician with prior work at the America First Policy Institute, as FDA commissioner on August 18-19, 2026, shortly after former commissioner Marty Makary’s May resignation left Kyle Diamantas as acting head. The Senate confirmation process, led by the HELP Committee under Sen. Bill Cassidy, represents the central hurdle. Cassidy has publicly voiced strong reservations over Overton’s involvement in a recent childhood vaccine schedule executive order and her limited senior managerial experience at the agency level. Administration allies, including HHS Secretary Robert F. Kennedy Jr., have endorsed her alignment with administration health priorities. No hearing dates have been set, and committee or floor timelines remain fluid amid a narrowly Republican-controlled Senate.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गयानया
30 सित, 2026
30 सितंबर
51%
31 अक्टूबर
52%
30 नवंबर
70%
31 दिसंबर
75%
$597 वॉल्यूम
30 सितंबर
$575 वॉल्यूम
51%
31 अक्टूबर
$11 वॉल्यूम
52%
30 नवंबर
$0 वॉल्यूम
70%
31 दिसंबर
$11 वॉल्यूम
75%
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by October 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.President Trump nominated Dr. Heidi Overton, deputy director of the White House Domestic Policy Council and a physician with prior work at the America First Policy Institute, as FDA commissioner on August 18-19, 2026, shortly after former commissioner Marty Makary’s May resignation left Kyle Diamantas as acting head. The Senate confirmation process, led by the HELP Committee under Sen. Bill Cassidy, represents the central hurdle. Cassidy has publicly voiced strong reservations over Overton’s involvement in a recent childhood vaccine schedule executive order and her limited senior managerial experience at the agency level. Administration allies, including HHS Secretary Robert F. Kennedy Jr., have endorsed her alignment with administration health priorities. No hearing dates have been set, and committee or floor timelines remain fluid amid a narrowly Republican-controlled Senate.
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
बाज़ार खुला: Aug 20, 2026, 5:43 PM ET
वॉल्यूम
$597समाप्ति तिथि
1 जन, 2027बाज़ार खुला
Aug 20, 2026, 5:43 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by October 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.President Trump nominated Dr. Heidi Overton, deputy director of the White House Domestic Policy Council and a physician with prior work at the America First Policy Institute, as FDA commissioner on August 18-19, 2026, shortly after former commissioner Marty Makary’s May resignation left Kyle Diamantas as acting head. The Senate confirmation process, led by the HELP Committee under Sen. Bill Cassidy, represents the central hurdle. Cassidy has publicly voiced strong reservations over Overton’s involvement in a recent childhood vaccine schedule executive order and her limited senior managerial experience at the agency level. Administration allies, including HHS Secretary Robert F. Kennedy Jr., have endorsed her alignment with administration health priorities. No hearing dates have been set, and committee or floor timelines remain fluid amid a narrowly Republican-controlled Senate.
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
वॉल्यूम
$597समाप्ति तिथि
1 जन, 2027बाज़ार खुला
Aug 20, 2026, 5:43 PM ETResolver
0x65070BE91...President Trump nominated Dr. Heidi Overton, deputy director of the White House Domestic Policy Council and a physician with prior work at the America First Policy Institute, as FDA commissioner on August 18-19, 2026, shortly after former commissioner Marty Makary’s May resignation left Kyle Diamantas as acting head. The Senate confirmation process, led by the HELP Committee under Sen. Bill Cassidy, represents the central hurdle. Cassidy has publicly voiced strong reservations over Overton’s involvement in a recent childhood vaccine schedule executive order and her limited senior managerial experience at the agency level. Administration allies, including HHS Secretary Robert F. Kennedy Jr., have endorsed her alignment with administration health priorities. No hearing dates have been set, and committee or floor timelines remain fluid amid a narrowly Republican-controlled Senate.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न